Daily phosphodiesterase type 5 inhibitor therapy: a new treatment option for prostatitis/prostatodynia?

E-ISSN： 2044-3749|6|3|40-41

ISSN： 2044-3730

Source： TRENDS IN UROLOGY AND MEN'S HEALTH, Vol.6, Iss.3, 2015-03, pp. : 40-41

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Couples' Satisfaction with Tadalafil Once Daily

THE JOURNAL OF SEXUAL MEDICINE, Vol. 12, Iss. 3, 2015-03 ,pp. : 720-727

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction

By Axilrod Andrew C.

Current Medical Research and Opinion, Vol. 23, Iss. 12, 2007-12 ,pp. : 3189-3198

Informa Healthcare

Access to resources Recommend Favorite

Photodynamic Therapy – a New Treatment Option for Epithelial Malignancies of the Skin

Oncology Research and Treatment, Vol. 27, Iss. 4, 2004-09 ,pp. : 407-411

Karger

Access to resources Recommend Favorite

Combination therapy with selective serotonin reuptake inhibitors and phosphodiesterase‐5 inhibitors in the treatment of premature ejaculation

ANDROLOGIA (ELECTRONIC), Vol. 47, Iss. 5, 2015-06 ,pp. : 487-492

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk–benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 4, 2015-04 ,pp. : 436-443

John Wiley & Sons Inc

Access to resources Recommend Favorite